268 related articles for article (PubMed ID: 24021215)
21. ABCG2: determining its relevance in clinical drug resistance.
Robey RW; Polgar O; Deeken J; To KW; Bates SE
Cancer Metastasis Rev; 2007 Mar; 26(1):39-57. PubMed ID: 17323127
[TBL] [Abstract][Full Text] [Related]
22. Human multidrug transporter ABCG2, a target for sensitizing drug resistance in cancer chemotherapy.
Xu J; Peng H; Zhang JT
Curr Med Chem; 2007; 14(6):689-701. PubMed ID: 17346156
[TBL] [Abstract][Full Text] [Related]
23. ABCG2 -- a transporter for all seasons.
Sarkadi B; Ozvegy-Laczka C; Német K; Váradi A
FEBS Lett; 2004 Jun; 567(1):116-20. PubMed ID: 15165903
[TBL] [Abstract][Full Text] [Related]
24. The challenge of exploiting ABCG2 in the clinic.
Robey RW; Ierano C; Zhan Z; Bates SE
Curr Pharm Biotechnol; 2011 Apr; 12(4):595-608. PubMed ID: 21118093
[TBL] [Abstract][Full Text] [Related]
25. Tandutinib (MLN518/CT53518) targeted to stem-like cells by inhibiting the function of ATP-binding cassette subfamily G member 2.
Zhao XQ; Dai CL; Ohnuma S; Liang YJ; Deng W; Chen JJ; Zeng MS; Ambudkar SV; Chen ZS; Fu LW
Eur J Pharm Sci; 2013 Jun; 49(3):441-50. PubMed ID: 23619284
[TBL] [Abstract][Full Text] [Related]
26. Multidrug resistance and cancer: the role of the human ABC transporter ABCG2.
Ejendal KF; Hrycyna CA
Curr Protein Pept Sci; 2002 Oct; 3(5):503-11. PubMed ID: 12369998
[TBL] [Abstract][Full Text] [Related]
27. Complete reversal of ABCG2-depending atypical multidrug resistance by RNA interference in human carcinoma cells.
Priebsch A; Rompe F; Tönnies H; Kowalski P; Surowiak P; Stege A; Materna V; Lage H
Oligonucleotides; 2006; 16(3):263-74. PubMed ID: 16978089
[TBL] [Abstract][Full Text] [Related]
28. ABCG2: structure, function and role in drug response.
Polgar O; Robey RW; Bates SE
Expert Opin Drug Metab Toxicol; 2008 Jan; 4(1):1-15. PubMed ID: 18370855
[TBL] [Abstract][Full Text] [Related]
29. Raltegravir permeability across blood-tissue barriers and the potential role of drug efflux transporters.
Hoque MT; Kis O; De Rosa MF; Bendayan R
Antimicrob Agents Chemother; 2015 May; 59(5):2572-82. PubMed ID: 25691630
[TBL] [Abstract][Full Text] [Related]
30. [Drug resistance mediated by ABC transporters].
Yoshikawa M; Ito A; Ishikawa T; Ikegami Y
Gan To Kagaku Ryoho; 2004 Jan; 31(1):1-6. PubMed ID: 14750312
[TBL] [Abstract][Full Text] [Related]
31. Gefitinib inhibition of drug resistance to doxorubicin by inactivating ABCG2 in thyroid cancer cell lines.
Lopez JP; Wang-Rodriguez J; Chang C; Chen JS; Pardo FS; Aguilera J; Ongkeko WM
Arch Otolaryngol Head Neck Surg; 2007 Oct; 133(10):1022-7. PubMed ID: 17938326
[TBL] [Abstract][Full Text] [Related]
32. Overexpression of the ATP-binding cassette half-transporter, ABCG2 (Mxr/BCrp/ABCP1), in flavopiridol-resistant human breast cancer cells.
Robey RW; Medina-Pérez WY; Nishiyama K; Lahusen T; Miyake K; Litman T; Senderowicz AM; Ross DD; Bates SE
Clin Cancer Res; 2001 Jan; 7(1):145-52. PubMed ID: 11205902
[TBL] [Abstract][Full Text] [Related]
33. BCRP/ABCG2 inhibitors: a patent review (2009-present).
Wiese M
Expert Opin Ther Pat; 2015; 25(11):1229-37. PubMed ID: 26291461
[TBL] [Abstract][Full Text] [Related]
34. ABCG2: a perspective.
Robey RW; To KK; Polgar O; Dohse M; Fetsch P; Dean M; Bates SE
Adv Drug Deliv Rev; 2009 Jan; 61(1):3-13. PubMed ID: 19135109
[TBL] [Abstract][Full Text] [Related]
35. LRIG1, human EGFR inhibitor, reverses multidrug resistance through modulation of ABCB1 and ABCG2.
Liu B; Guo Z; Dong H; Daofeng T; Cai Q; Ji B; Zhang S; Wu L; Wang J; Wang L; Zhu X; Liu Y; Chen Q
Brain Res; 2015 Jun; 1611():93-100. PubMed ID: 25801120
[TBL] [Abstract][Full Text] [Related]
36. Tyrosine kinase inhibitors influence ABCG2 expression in EGFR-positive MDCK BCRP cells via the PI3K/Akt signaling pathway.
Pick A; Wiese M
ChemMedChem; 2012 Apr; 7(4):650-62. PubMed ID: 22354538
[TBL] [Abstract][Full Text] [Related]
37. Identification of compounds that correlate with ABCG2 transporter function in the National Cancer Institute Anticancer Drug Screen.
Deeken JF; Robey RW; Shukla S; Steadman K; Chakraborty AR; Poonkuzhali B; Schuetz EG; Holbeck S; Ambudkar SV; Bates SE
Mol Pharmacol; 2009 Nov; 76(5):946-56. PubMed ID: 19633067
[TBL] [Abstract][Full Text] [Related]
38. Structure and function of the human breast cancer resistance protein (BCRP/ABCG2).
Ni Z; Bikadi Z; Rosenberg MF; Mao Q
Curr Drug Metab; 2010 Sep; 11(7):603-17. PubMed ID: 20812902
[TBL] [Abstract][Full Text] [Related]
39. Elacridar enhances the cytotoxic effects of sunitinib and prevents multidrug resistance in renal carcinoma cells.
Sato H; Siddig S; Uzu M; Suzuki S; Nomura Y; Kashiba T; Gushimiyagi K; Sekine Y; Uehara T; Arano Y; Yamaura K; Ueno K
Eur J Pharmacol; 2015 Jan; 746():258-66. PubMed ID: 25455500
[TBL] [Abstract][Full Text] [Related]
40. Human ABC transporter ABCG2 in cancer chemotherapy: drug molecular design to circumvent multidrug resistance.
Ishikawa T; Saito H; Hirano H; Inoue Y; Ikegami Y
Methods Mol Biol; 2012; 910():267-78. PubMed ID: 22821599
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
